HURA

TuHURA Biosciences, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer. The company's pipeline includes multiple product candidates targeting various oncology indications, with a focus on small molecule inhibitors and novel mechanisms of action. TuHURA's lead programs include IMP-1734, an oral inhibitor being developed for solid tumors, and other candidates in preclinical and clinical development stages. The company utilizes a platform approach to drug discovery and development, focusing on precision medicine and biomarker-driven patient selection. TuHURA Biosciences was formerly known as Coronado Biosciences and rebranded to reflect its new strategic focus on oncology therapeutics. The company is headquartered in San Diego, California.